Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Pfizer
• Treatments: Eletriptan

Criteria

Inclusion Criteria:

• age 18-45 healthy menstruating female

Exclusion Criteria:

• cardiac or other conditions precluding use of eletriptan